JP2008545654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008545654A5 JP2008545654A5 JP2008512476A JP2008512476A JP2008545654A5 JP 2008545654 A5 JP2008545654 A5 JP 2008545654A5 JP 2008512476 A JP2008512476 A JP 2008512476A JP 2008512476 A JP2008512476 A JP 2008512476A JP 2008545654 A5 JP2008545654 A5 JP 2008545654A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- dihydropyridine
- oxo
- fluoro
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 66
- -1 2-fluoro-4- (methylthio) phenylamino Chemical group 0.000 claims 17
- 150000001408 amides Chemical class 0.000 claims 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 238000002441 X-ray diffraction Methods 0.000 claims 6
- 239000007822 coupling agent Substances 0.000 claims 5
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052763 palladium Inorganic materials 0.000 claims 3
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 claims 2
- ICXZCGXSOXMFBC-UHFFFAOYSA-N CC=1N(C(C=CC1C(=O)N)=O)C Chemical compound CC=1N(C(C=CC1C(=O)N)=O)C ICXZCGXSOXMFBC-UHFFFAOYSA-N 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000031709 bromination Effects 0.000 claims 2
- 238000005893 bromination reaction Methods 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000004820 halides Chemical group 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- JZBQFLNWUKMAKK-UHFFFAOYSA-N n-(2-ethenoxyethoxy)-2-(2-fluoro-4-iodoanilino)-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCOC=C)=C1NC1=CC=C(I)C=C1F JZBQFLNWUKMAKK-UHFFFAOYSA-N 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims 2
- LHWUAGUJWYLNNL-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-n-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1Cl LHWUAGUJWYLNNL-UHFFFAOYSA-N 0.000 claims 1
- AQPBVQMMZYZSLA-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-n-(2-hydroxyethoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=CC(=O)N(C)C(NC=2C(=CC(I)=CC=2)Cl)=C1C(=O)NOCCO AQPBVQMMZYZSLA-UHFFFAOYSA-N 0.000 claims 1
- YUIKGEAGXCVTLR-JTQLQIEISA-N 2-(2-chloro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound C1=C(C)C(=O)N(C)C(NC=2C(=CC(I)=CC=2)Cl)=C1C(=O)NOC[C@@H](O)C YUIKGEAGXCVTLR-JTQLQIEISA-N 0.000 claims 1
- BOXZLZXQVSFYCS-VIFPVBQESA-N 2-(2-chloro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=CC(=O)N(C)C(NC=2C(=CC(I)=CC=2)Cl)=C1C(=O)NOC[C@@H](O)C BOXZLZXQVSFYCS-VIFPVBQESA-N 0.000 claims 1
- NAMRBZNINMQMQI-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound CN1C(=O)C(C)=CC(C(N)=O)=C1NC1=CC=C(I)C=C1F NAMRBZNINMQMQI-UHFFFAOYSA-N 0.000 claims 1
- UFYHNTBWMOLAFZ-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=CC(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOCCO UFYHNTBWMOLAFZ-UHFFFAOYSA-N 0.000 claims 1
- HZTGWVZQZRYCIJ-JTQLQIEISA-N 2-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound C1=C(C)C(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOC[C@@H](O)C HZTGWVZQZRYCIJ-JTQLQIEISA-N 0.000 claims 1
- SFYAWJWIRRKIGT-VIFPVBQESA-N 2-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=CC(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOC[C@@H](O)C SFYAWJWIRRKIGT-VIFPVBQESA-N 0.000 claims 1
- ZFURDWPQBHLAJG-UHFFFAOYSA-N 2-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)C=C(C)C(=O)N1C ZFURDWPQBHLAJG-UHFFFAOYSA-N 0.000 claims 1
- VSVSQTSOMXDCEP-UHFFFAOYSA-N 2-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)C=CC(=O)N1C VSVSQTSOMXDCEP-UHFFFAOYSA-N 0.000 claims 1
- QKZGOLDDVJWDRG-NSHDSACASA-N 2-(2-fluoro-4-methylsulfanylanilino)-n-[(2s)-2-hydroxypropoxy]-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOC[C@H](C)O)C=C(C)C(=O)N1C QKZGOLDDVJWDRG-NSHDSACASA-N 0.000 claims 1
- GXCXKKDPOHSMKY-JTQLQIEISA-N 2-(2-fluoro-4-methylsulfanylanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOC[C@H](C)O)C=CC(=O)N1C GXCXKKDPOHSMKY-JTQLQIEISA-N 0.000 claims 1
- RMWAGHMXANQTBX-UHFFFAOYSA-N 5-chloro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=C(Cl)C(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOCCO RMWAGHMXANQTBX-UHFFFAOYSA-N 0.000 claims 1
- PKGUFCFNPBLKAQ-QMMMGPOBSA-N 5-chloro-2-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=C(Cl)C(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOC[C@@H](O)C PKGUFCFNPBLKAQ-QMMMGPOBSA-N 0.000 claims 1
- HSVJEISLTOFHPB-UHFFFAOYSA-N 5-fluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxypropoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=C(F)C(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOCC(O)C HSVJEISLTOFHPB-UHFFFAOYSA-N 0.000 claims 1
- OVVOSACGKCNWKT-UHFFFAOYSA-N 5-fluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound C1=C(F)C(=O)N(C)C(NC=2C(=CC(I)=CC=2)F)=C1C(=O)NOCCO OVVOSACGKCNWKT-UHFFFAOYSA-N 0.000 claims 1
- KZPVGTXIQWCSNW-UHFFFAOYSA-N 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)-1-methyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)C=C(F)C(=O)N1C KZPVGTXIQWCSNW-UHFFFAOYSA-N 0.000 claims 1
- UIYYKSUHRZUEQP-VIFPVBQESA-N 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOC[C@H](C)O)C=C(F)C(=O)N1C UIYYKSUHRZUEQP-VIFPVBQESA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 0 CN(C(C(Br)=C1)=O)C(Cl)=C1C(O*)=O Chemical compound CN(C(C(Br)=C1)=O)C(Cl)=C1C(O*)=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68233505P | 2005-05-18 | 2005-05-18 | |
| US60/682,335 | 2005-05-18 | ||
| PCT/US2006/019108 WO2007044084A2 (en) | 2005-05-18 | 2006-05-17 | Heterocyclic inhibitors of mek and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009120619A Division JP5089649B2 (ja) | 2005-05-18 | 2009-05-19 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
| JP2012220857A Division JP5576919B2 (ja) | 2005-05-18 | 2012-10-03 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008545654A JP2008545654A (ja) | 2008-12-18 |
| JP2008545654A5 true JP2008545654A5 (https=) | 2009-07-02 |
| JP5270336B2 JP5270336B2 (ja) | 2013-08-21 |
Family
ID=37943261
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512476A Expired - Fee Related JP5270336B2 (ja) | 2005-05-18 | 2006-05-17 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
| JP2009120619A Expired - Fee Related JP5089649B2 (ja) | 2005-05-18 | 2009-05-19 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
| JP2012220857A Expired - Fee Related JP5576919B2 (ja) | 2005-05-18 | 2012-10-03 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009120619A Expired - Fee Related JP5089649B2 (ja) | 2005-05-18 | 2009-05-19 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
| JP2012220857A Expired - Fee Related JP5576919B2 (ja) | 2005-05-18 | 2012-10-03 | Ｍｅｋの複素環式阻害剤及びその使用方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8299076B2 (https=) |
| EP (4) | EP1922307B1 (https=) |
| JP (3) | JP5270336B2 (https=) |
| KR (3) | KR20110074772A (https=) |
| CN (5) | CN102942522A (https=) |
| AR (3) | AR055057A1 (https=) |
| AT (2) | ATE539064T1 (https=) |
| AU (1) | AU2006299902B2 (https=) |
| BR (1) | BRPI0610139A2 (https=) |
| CA (1) | CA2608201C (https=) |
| CL (2) | CL2008003486A1 (https=) |
| CY (1) | CY1112297T1 (https=) |
| DE (1) | DE602006010243D1 (https=) |
| DK (1) | DK1922307T3 (https=) |
| EC (1) | ECSP078013A (https=) |
| ES (4) | ES2333182T3 (https=) |
| HR (1) | HRP20120154T1 (https=) |
| IL (3) | IL187353A (https=) |
| MY (2) | MY149957A (https=) |
| NO (1) | NO20076412L (https=) |
| NZ (3) | NZ587189A (https=) |
| PL (3) | PL2364973T3 (https=) |
| PT (2) | PT1922307E (https=) |
| RS (1) | RS52243B (https=) |
| RU (4) | RU2500673C2 (https=) |
| SA (1) | SA06270141B1 (https=) |
| SG (2) | SG177981A1 (https=) |
| SI (1) | SI1922307T1 (https=) |
| TW (3) | TWI506020B (https=) |
| UA (2) | UA100007C2 (https=) |
| WO (1) | WO2007044084A2 (https=) |
| ZA (2) | ZA200710318B (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| CA2546353A1 (en) * | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| WO2008140553A2 (en) | 2006-10-23 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| GB0625691D0 (en) * | 2006-12-22 | 2007-01-31 | Astrazeneca Ab | Combination product |
| WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| US20100130519A1 (en) * | 2007-04-13 | 2010-05-27 | Stephen Robert Wedge | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii |
| WO2009050506A2 (en) * | 2007-10-15 | 2009-04-23 | Astrazeneca Ab | Combination 059 |
| WO2009064675A1 (en) * | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| EP2231281A2 (en) * | 2007-12-12 | 2010-09-29 | AstraZeneca AB | Combination comprising a mek inhibitor and an aurora kinase inhibitor |
| KR20110028651A (ko) | 2008-07-11 | 2011-03-21 | 노파르티스 아게 | (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물 |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| CN106478496A (zh) * | 2009-03-27 | 2017-03-08 | 阿迪生物科学公司 | 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺 |
| CN102020851B (zh) | 2009-09-16 | 2013-10-16 | 大连路明发光科技股份有限公司 | 一种光转换柔性高分子材料及其用途 |
| EP3028699B1 (en) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| EP2614053B1 (en) | 2010-09-08 | 2016-03-23 | Sumitomo Chemical Company Limited | Method for producing pyridazinone compounds and intermediates thereof |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| WO2012087965A2 (en) | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| CN102358730A (zh) * | 2011-08-24 | 2012-02-22 | 济南赛文医药技术有限公司 | 一种小分子mek蛋白激酶抑制剂 |
| CN103764144B (zh) | 2011-08-31 | 2016-07-20 | 诺华股份有限公司 | Pi3k抑制剂与mek抑制剂的协同组合 |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| BR112015012497B1 (pt) | 2012-11-29 | 2022-05-17 | Novartis Ag | Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial |
| TW201441193A (zh) | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | 吡啶酮化合物 |
| PT2975030T (pt) * | 2013-03-13 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Derivado de di-hidropiridazina-3,5-diona |
| WO2014204263A1 (en) | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| BR112016007396B1 (pt) * | 2013-10-25 | 2021-01-19 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Composto de fórmula (ii), seu processo de preparação e seu uso, composto de fórmula(iia) e composição farmacêutica |
| CA2935804A1 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| WO2015131080A1 (en) * | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| RU2020142739A (ru) | 2015-08-28 | 2021-01-15 | Новартис Аг | Ингибиторы mdm2 и их комбинации |
| SG10202111851YA (en) | 2015-10-16 | 2021-12-30 | Fate Therapeutics Inc | Platform for the Induction & Maintenance of Ground State Pluripotency |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3377470B1 (en) * | 2015-11-18 | 2020-11-11 | FMC Corporation | Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives |
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| WO2017154001A1 (en) * | 2016-03-10 | 2017-09-14 | Lutris Pharma Ltd. | Use of braf inhibitors for treating cutaneous reactions |
| WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| KR102435424B1 (ko) * | 2017-09-13 | 2022-08-23 | 엘지디스플레이 주식회사 | 듀티 구동 기능을 갖는 표시장치 및 이의 구동방법 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| EP4346826A4 (en) | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| IL316768A (en) | 2022-05-25 | 2025-01-01 | Ikena Oncology Inc | MEK inhibitors and their uses |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3682932A (en) | 1970-11-23 | 1972-08-08 | Hoffmann La Roche | 2-chloro-6-hydroxynicotinic acid |
| DE2150772A1 (de) | 1971-10-12 | 1973-04-19 | Cassella Farbwerke Mainkur Ag | Verfahren zur herstellung von 6-hydroxy-2-pyridon-3-carbonsaeureamidverbindungen |
| DE2307169A1 (de) | 1973-02-14 | 1974-09-26 | Bayer Ag | Azofarbstoffe |
| AT392789B (de) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten |
| US4851535A (en) * | 1985-01-23 | 1989-07-25 | Toyama Chemical Co., Ltd. | Nicotinic acid derivatives |
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| FR2687676B1 (fr) * | 1992-02-24 | 1994-07-08 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| WO1995003286A1 (en) | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| KR100330553B1 (ko) * | 1993-10-01 | 2002-11-27 | 노파르티스 아게 | 약물학적활성피리딘유도체및그의제조방법 |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| EP0977733B1 (en) | 1997-02-03 | 2003-09-03 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| EA002546B1 (ru) | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Производные арилсульфонилгидроксамовой кислоты |
| DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| CA2290509A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU730248B2 (en) | 1997-08-08 | 2001-03-01 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| AUPP466598A0 (en) | 1998-07-14 | 1998-08-06 | University Of Newcastle Research Associates Limited, The | Product and process |
| DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
| AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| JP2002534380A (ja) * | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による喘息の治療 |
| EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
| CA2349832A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2355470C (en) * | 1999-01-13 | 2008-09-30 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
| HUP0105092A3 (en) | 1999-01-13 | 2003-12-29 | Warner Lambert Co | 1-heterocycle substituted diarylamines and medicaments containing them |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| EP1144372B1 (en) * | 1999-01-13 | 2005-11-30 | Warner-Lambert Company Llc | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| EP1202732A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| CA2377092A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| JP2003504400A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いた慢性痛の治療方法 |
| US7030119B1 (en) * | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| SI1255752T1 (sl) | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| EP1339702A1 (en) * | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| RU2167659C1 (ru) * | 2000-08-02 | 2001-05-27 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ коррекции иммунной системы живого организма |
| KR20030059115A (ko) | 2000-08-25 | 2003-07-07 | 워너-램버트 캄파니 엘엘씨 | Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법 |
| EP1337524A1 (en) * | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
| US6642215B2 (en) * | 2001-05-24 | 2003-11-04 | Leo Pharma A/S | Method of modulating NF-kB activity |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| MXPA04008822A (es) | 2002-03-14 | 2004-11-26 | Bayer Healthcare Ag | Aroilpiridinonas monociclicas. |
| WO2004000529A1 (de) | 2002-06-24 | 2003-12-31 | Fagerdala Deutschland Gmbh | Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten |
| WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| CA2546353A1 (en) * | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
-
2006
- 2006-05-17 SG SG2012002887A patent/SG177981A1/en unknown
- 2006-05-17 MY MYPI20062270A patent/MY149957A/en unknown
- 2006-05-17 NZ NZ587189A patent/NZ587189A/en not_active IP Right Cessation
- 2006-05-17 EP EP06836069A patent/EP1922307B1/en active Active
- 2006-05-17 RU RU2009118281/04A patent/RU2500673C2/ru not_active IP Right Cessation
- 2006-05-17 US US11/914,433 patent/US8299076B2/en not_active Expired - Fee Related
- 2006-05-17 CA CA2608201A patent/CA2608201C/en not_active Expired - Fee Related
- 2006-05-17 CN CN2012103757743A patent/CN102942522A/zh active Pending
- 2006-05-17 EP EP11003826.2A patent/EP2364973B1/en active Active
- 2006-05-17 ES ES08004958T patent/ES2333182T3/es active Active
- 2006-05-17 TW TW101118139A patent/TWI506020B/zh not_active IP Right Cessation
- 2006-05-17 EP EP11003827A patent/EP2361905B1/en active Active
- 2006-05-17 RS RS20120090A patent/RS52243B/sr unknown
- 2006-05-17 ES ES11003827T patent/ES2405785T3/es active Active
- 2006-05-17 JP JP2008512476A patent/JP5270336B2/ja not_active Expired - Fee Related
- 2006-05-17 AT AT06836069T patent/ATE539064T1/de active
- 2006-05-17 PT PT06836069T patent/PT1922307E/pt unknown
- 2006-05-17 CN CN200680026372A patent/CN101626767A/zh active Pending
- 2006-05-17 RU RU2007146115/04A patent/RU2414455C2/ru not_active IP Right Cessation
- 2006-05-17 MY MYPI2010001331A patent/MY149960A/en unknown
- 2006-05-17 CN CN2011102242374A patent/CN102304086B/zh not_active Expired - Fee Related
- 2006-05-17 ES ES06836069T patent/ES2378760T3/es active Active
- 2006-05-17 KR KR1020117011251A patent/KR20110074772A/ko not_active Ceased
- 2006-05-17 PT PT110038270T patent/PT2361905E/pt unknown
- 2006-05-17 TW TW101118140A patent/TW201238952A/zh unknown
- 2006-05-17 TW TW095117459A patent/TWI441637B/zh not_active IP Right Cessation
- 2006-05-17 KR KR1020117011249A patent/KR20110074908A/ko not_active Ceased
- 2006-05-17 DE DE602006010243T patent/DE602006010243D1/de active Active
- 2006-05-17 SI SI200631291T patent/SI1922307T1/sl unknown
- 2006-05-17 HR HR20120154T patent/HRP20120154T1/hr unknown
- 2006-05-17 AR ARP060101994A patent/AR055057A1/es not_active Application Discontinuation
- 2006-05-17 EP EP08004958A patent/EP1967516B1/en active Active
- 2006-05-17 WO PCT/US2006/019108 patent/WO2007044084A2/en not_active Ceased
- 2006-05-17 NZ NZ587190A patent/NZ587190A/en not_active IP Right Cessation
- 2006-05-17 UA UAA200904802A patent/UA100007C2/ru unknown
- 2006-05-17 ES ES11003826.2T patent/ES2500068T3/es active Active
- 2006-05-17 PL PL11003826T patent/PL2364973T3/pl unknown
- 2006-05-17 PL PL11003827T patent/PL2361905T3/pl unknown
- 2006-05-17 AT AT08004958T patent/ATE447559T1/de not_active IP Right Cessation
- 2006-05-17 CN CN201110224236XA patent/CN102321030A/zh active Pending
- 2006-05-17 SG SG201002953-6A patent/SG161318A1/en unknown
- 2006-05-17 AU AU2006299902A patent/AU2006299902B2/en not_active Ceased
- 2006-05-17 UA UAA200712647A patent/UA93678C2/ru unknown
- 2006-05-17 KR KR1020077029520A patent/KR20080019236A/ko not_active Abandoned
- 2006-05-17 DK DK06836069.2T patent/DK1922307T3/da active
- 2006-05-17 BR BRPI0610139-9A patent/BRPI0610139A2/pt not_active IP Right Cessation
- 2006-05-17 PL PL06836069T patent/PL1922307T3/pl unknown
- 2006-05-17 SA SA06270141A patent/SA06270141B1/ar unknown
- 2006-05-17 CN CN2012103746556A patent/CN102898364A/zh active Pending
- 2006-05-17 NZ NZ563707A patent/NZ563707A/en not_active IP Right Cessation
-
2007
- 2007-04-28 ZA ZA2007/10318A patent/ZA200710318B/en unknown
- 2007-11-13 IL IL187353A patent/IL187353A/en not_active IP Right Cessation
- 2007-12-12 NO NO20076412A patent/NO20076412L/no not_active Application Discontinuation
- 2007-12-13 EC EC2007008013A patent/ECSP078013A/es unknown
-
2008
- 2008-11-21 CL CL2008003486A patent/CL2008003486A1/es unknown
-
2009
- 2009-05-19 JP JP2009120619A patent/JP5089649B2/ja not_active Expired - Fee Related
- 2009-10-23 CL CL2009001993A patent/CL2009001993A1/es unknown
-
2010
- 2010-07-12 RU RU2010128512/04A patent/RU2010128512A/ru not_active Application Discontinuation
- 2010-11-02 RU RU2010144823/04A patent/RU2010144823A/ru not_active Application Discontinuation
-
2011
- 2011-04-14 IL IL212396A patent/IL212396A/en not_active IP Right Cessation
- 2011-04-14 IL IL212398A patent/IL212398A/en not_active IP Right Cessation
- 2011-08-31 AR ARP110103181A patent/AR082825A2/es not_active Application Discontinuation
- 2011-08-31 AR ARP110103182A patent/AR082826A2/es not_active Application Discontinuation
-
2012
- 2012-01-31 CY CY20121100105T patent/CY1112297T1/el unknown
- 2012-05-25 ZA ZA2012/03844A patent/ZA201203844B/en unknown
- 2012-10-03 JP JP2012220857A patent/JP5576919B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008545654A5 (https=) | ||
| RU2007146115A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| CA2834928C (en) | Compounds for inflammation and immune-related uses | |
| TWI422579B (zh) | 新化合物 | |
| JP2011529049A5 (https=) | ||
| CN1140528C (zh) | 制备除草剂衍生物的方法 | |
| CN102341378B (zh) | 1-烷基-5-苯甲酰基-1h-四唑衍生物的制备方法 | |
| JP2013521301A5 (https=) | ||
| WO2003037881A1 (en) | α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | |
| JP2007515465A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| JP2013510884A5 (https=) | ||
| JP2011500513A5 (https=) | ||
| JP2013541592A5 (https=) | ||
| JP2000515133A (ja) | 血糖降下性および脂質低下性の化合物 | |
| JP2008508247A5 (https=) | ||
| RU2004117595A (ru) | Производные пиридина в качестве лигандов рецептора nmda | |
| JP2005533064A5 (https=) | ||
| JP6302937B2 (ja) | ２−（（１ｒ，４ｒ）−４−（４−（５−（ベンゾオキサゾール−２−イルアミノ）ピリジン−２−イル）フェニル）シクロヘキシル）酢酸のメグルミン塩形態、およびｄｇａｔ１阻害剤としてのそれらの使用 | |
| JP2011507847A5 (https=) | ||
| JP2005508382A5 (https=) | ||
| JP2012096999A (ja) | ニッケル触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法 | |
| JP5740042B2 (ja) | 化合物、化合物の製造方法、及び化合物の精製方法 | |
| RU2012153702A (ru) | Соединения, обладающие активирующим действием на подтипы рецепторов, активируемых пролифератором пероксисом (ppars), и способ получения и применения указанных соединений | |
| JP2006516588A5 (https=) |